Lidocaine/dextromethorphan - Endo/Indevus

Drug Profile

Lidocaine/dextromethorphan - Endo/Indevus

Alternative Names: LidodexNS

Latest Information Update: 19 Sep 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endo Pharmaceuticals; Indevus Pharmaceuticals
  • Class Antimigraines; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action NMDA receptor antagonists; Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 19 Sep 2003 Discontinued - Preclinical for Migraine in USA (Intranasal)
  • 15 May 2002 Interneuron Pharmaceuticals is now called Indevus Pharmaceuticals
  • 31 Dec 2001 Endo has been merged with and into Endo Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top